Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067233 | 1.00 | MMP13 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL7525866 | 1.00 | MMP13 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL2239710 | 0.91 | GSTP1 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL2239712 | 0.91 | GSTP1 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL5147914 | 0.90 | ALDH1A1 (0.55) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460172 | 0.90 | MMP13 (0.46) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL18811796 | 0.90 | THRB (0.46) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460171 | 0.89 | CA1 (0.45) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460170 | 0.89 | CA1 (0.45) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL28085110 | 0.85 | MMP13 (0.52) | MMP13CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111606970-B | 1, 5-diazabicyclo [5,3,0] decarenone amino acid derivative and preparation method and application thereof | 中国药科大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-111606970-A | 1, 5-diazabicyclo [5,3,0] deca-alkanone amino acid derivative and preparation method and application thereof | 中国药科大学 | 2020-09-01 | — | — | CN | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9493477-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| EP-2475429-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | SIGNATURE THERAPEUTICS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2560490-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560489-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120230916-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2012-09-13 | — | — | US | disclosed |
| EP-2475429-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133150-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011031350-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230916-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | MMP13 423/4885CA1 402/4885CA2 1300/4885 |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | MMP13 423/4885CA1 402/4885CA2 1300/4885 |
| US-20130210701-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | MMP13 98/4885CA1 348/4885CA2 812/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | MMP13 142/4885CA1 232/4885CA2 732/4885 |
| US-20130210854-A1 | Compositions Comprising Enzyme-Cleavable Prodrugs of Active Agents and Inhibitors Thereof | PEPD, TMPRSS15, ADAM17 | MMP13 142/4885CA1 232/4885CA2 732/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | MMP13 98/4885CA1 348/4885CA2 812/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | MMP13 98/4885CA1 348/4885CA2 812/4885 |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | ACHE, CYP2C18, CYP2C9 | MMP13 423/4885CA1 402/4885CA2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.